Clinical Trials Logo

Citation(s)

A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Details for clinical trial NCT00317811